EUVIMEDEUVIMED entdecken
Crossref

Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis

Jianzhou Liu, Bolun Jiang, Wenchao Xu, Qiaofei Liu, Haoran Huang, Xiaoyan Chang, Guoxu Ma, Xudong Xu, Li Zhou, Gary Guishan Xiao, Junchao Guo

Cancer Letters · 2024-11 · 605 · 217280

DOI: 10.1016/j.canlet.2024.217280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Jianzhou Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Key Laboratory of Research in Pancreatic Tumor, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, TOR Serine-Threonine Kinases, Choline Kinase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic malignancy for which there are currently no effective anti-metastatic therapies. Herein, we employed single-cell RNA sequencing and metabolomics analysis to demonstrate that metastatic cells highly express focal adhesion kinase (FAK), which promotes metastasis by remodeling choline kinase α (CHKα)-dependent choline metabolism. We designed a novel CHKα inhibitor, CHKI-03, and verified its efficacy in inhibiting metastasis in multiple preclinical models. Classical and newly synthesized small-molecule inhibitors have previously been used to assess the therapeutic potential of targeting mTOR and CHKα in various animal models. Mechanistically, FAK activated mTOR and its downstream HIF-1α, thereby elevating CHKα expression and promoting the proliferation, migration, and invasion of PDAC cells, as well as tumor growth and metastasis. Consistently, high expression levels of both FAK and CHKα are correlated with poor prognosis in patients with PDAC. Notably, CHK1-03 inhibited CHKα expression and also suppressed mTORC1 phosphorylation, disrupting the mTORC1-CHKα positive feedback loop. In addition, the combination of CHKI-03 and the mTORC1 inhibitor rapamycin synergistically inhibited tumor growth and metastasis in PDX models. The combination of CHKI-03 and rapamycin demonstrates considerable therapeutic efficacy in PDO models resistant to gemcitabine. Our findings reveal a pivotal mechanism underlying PDAC metastasis regulated by mTORC1-CHKα loop-dependent choline metabolism reprogramming, highlighting the therapeutic potential of this novel regimen for treating PDAC metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsTOR Serine-Threonine KinasesCholine KinaseHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysCell ProliferationFocal Adhesion Kinase 1Checkpoint Kinase 1Neoplasm MetastasisMechanistic Target of Rapamycin Complex 1GemcitabineProtein Kinase InhibitorsDeoxycytidineSignal TransductionCell MovementHypoxia-Inducible Factor 1, alpha SubunitFemale

Stichwörter der Autor:innen

Choline kinase inhibitorCholine kinase αMetastasisPancreatic ductal adenocarcinomamTOR

Substanzen

TOR Serine-Threonine KinasesCholine KinaseCHKA protein, humanMTOR protein, humanFocal Adhesion Kinase 1Checkpoint Kinase 1PTK2 protein, humanMechanistic Target of Rapamycin Complex 1CHEK1 protein, humanGemcitabine

Autor:innen und Institutionen

  • Department of General Surgery, Key Laboratory of Research in Pancreatic Tumor, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Pek…
  • Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 31003, China.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
  • Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of…
  • Functional Genomics and Proteomics Center, Creighton University Medical Center, 601N 30th ST, Omaha, NE, 68131, USA.

Zitieren

APA

Liu, J., Jiang, B., Xu, W., Liu, Q., Huang, H., Chang, X., Ma, G., Xu, X., Zhou, L., Xiao, G. G., & Guo, J. (2024). Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. Cancer Letters, 605, 217280. https://doi.org/10.1016/j.canlet.2024.217280

Vancouver

Liu J, Jiang B, Xu W, Liu Q, Huang H, Chang X, et al. Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. Cancer Letters. 2024;605:217280. doi:10.1016/j.canlet.2024.217280

BibTeX
@article{Liu2024,
  author = {Liu, Jianzhou and Jiang, Bolun and Xu, Wenchao and Liu, Qiaofei and Huang, Haoran and Chang, Xiaoyan and Ma, Guoxu and Xu, Xudong and Zhou, Li and Xiao, Gary Guishan and Guo, Junchao},
  title = {Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis},
  journal = {Cancer Letters},
  year = {2024},
  volume = {605},
  pages = {217280},
  doi = {10.1016/j.canlet.2024.217280}
}
Kostenlos starten →